BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate at the 2023 Wedbush PacGrow Healthcare Conference on Wednesday, August 9, 2023 at 9:30a.m. ET on the panel David vs. Goliath - How Can Orphan Epilepsy Development Accelerate and Broaden its Reach? Please contact your Wedbush representative for details about how to participate.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter.
Investor Contact Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact Ian Stone Canale Communications Ian.stone@canalecomm.com 619-849-5388
